Collective sensing and collective responses in quorum-sensing bacteria

por Popat, R., Cornforth, D. M., McNally, L., Brown, S. P.
Publicado 2015

Assessment of the young adult hip joint using plain radiographs

por Popat, R., Lee, S., George, D. A., Amiras, D., Sarraf, K. M.
Publicado 2020

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Fonseca, R., Kuroda, J., Ishida, T., Popat, R., Huang, J. S., Yver, A., Vandendries, E., Elmeliegy, M., Ma, W. D., Sborov, D. W.
Publicado 2022

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM...

por Quach, H., Gironella, M., Lee, C., Popat, R., Cannell, P., Kasinathan, R. S., Chopra, B., Rogers, R., Ferron-Brady, G., Shafi-Harji, S., Patel, N., Opalinska, J., Gupta, I., Augustson, B.
Publicado 2022

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

por Chin, M, Sive, J I, Allen, C, Roddie, C, Chavda, S J, Smith, D, Blombery, P, Jones, K, Ryland, G L, Popat, R, Rismani, A, D'Sa, S, Rabin, N, Gale, R E, Yong, K L
Publicado 2017

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)

por Searle, E., Quach, H., Wong, S., Costa, L., Hulin, C., Janowski, W., Berdeja, J., Anguille, S., Matous, J., Touzeau, C., Michallet, A., Husnik, M., Vishwamitra, D., Niu, Z., Larsen, J., Chen, L., Goldberg, J., Popat, R., Spencer, A.
Publicado 2023

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS

por Khwaja, J., Bomsztyk, J., Mahmood, S., Wisniowski, B., Shah, R., Tailor, A., Yong, K., Popat, R., Rabin, N., Kyriakou, C., Sive, J., Worthington, S., Hart, A., Dowling, E., Correia, N., Bygrave, C., Rydzewski, A., Jamroziak, K., Wechalekar, A.
Publicado 2022

P954: ESTABLISHING THE NATIONAL INSTITUTE FOR HEALTH RESEARCH (NIHR) HEALTH INFORMATICS COLLABORATIVE (HIC) MULTIPLE MYELOMA (MM) REGISTRY

por Tayabali, S., Moore, S., Jenner, M., Djebbari, F., Romao, L., English, L., Rodriguez, R., Briot Ribeyre, B., Roadknight, G., Varnai, K., Little, S., Davies, J., Woods, K., Davis, C., Borca, F., Olza Meneses, J., Phan, H., Wong, W. K., Popat, R.
Publicado 2022

P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

por van de Donk, N. W. C. J, Popat, R, Hulin, C, Jagannath, S, Oriol, A, Richardson, P. G, Facon, T, Weisel, K, Larsen, J. T, Minnema, M, Abdallah, A, Badros, A. Z, Knop, S, Stadtmauer, E. A, Chen, M, Nguyen, T. V, Amin, A, Peluso, T, Lonial, S
Publicado 2022

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

por Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Publicado 2023

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC...

por Martínez-López, J., Moreau, P., Usmani, S. Z., Garfall, A., van de Donk, N. W., San-Miguel, J. F., Oriol, A., Chari, A., Karlin, L., Mateos, M.-V., Popat, R., Nooka, A. K., Sidana, S., Trancucci, D., Verona, R., Girgis, S., Uhlar, C., Stephenson, T., Banerjee, A., Krishnan, A.
Publicado 2022

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

por Popat, R., Moreau, P., Usmani, S. Z., Garfall, A., Mateos, M.-V., San-Miguel, J. F., Oriol, A., Nooka, A. K., Rosinol, L., Chari, A., Karlin, L., Krishnan, A., Bahlis, N., Martin, T., Besemer, B., Martínez-López, J., Delforge, M., Fastenau, J., Gries, K. S., van de Donk, N. W.
Publicado 2022

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM...

por Popat, R, Usmani, S, Garfall, A, van de Donk, N, Nahi, H, San-Miguel, J, Oriol, A, Nooka, A, Martin, T, Rosinol, L, Chari, A, Karlin, L, Benboubker, L, Mateos, M, Bahlis, N, Moreau, P, Besemer, B, Martínez-López, J, Sidana, S, Pei, L, Trancucci, D, Verona, R, Girgis, S, Olyslager, Y, Jaffe, M, Uhlar, C, Stephenson, T, Van Rampelbergh, R, Banerjee, A, Goldberg, J, Kobos, R, Krishnan, A
Publicado 2022